“Hemophagocytic Lymphohistiocytosis after EBV reactivation and Ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”

We report the clinical course of a patient with relapsed CLL who developed acute symptoms soon after starting ibrutinib. Hyperpyrexia, splenomegaly, hyperferritinemia, hypertriglyceridemia, cytopenias, and a typical cytokine pattern, i.e. high interleukin (IL)− 6, IL10 and IL18, were consistent with a diagnosis of HLH. Coexistent Epstein Barr virus reactivation was documented. Ibrutinib-induced impairment of NK degranulation, associated with EBV reactivation and CLL-related immunodeficiency may have contributed to the development of HLH in our patient.
Source: Leukemia Research Reports - Category: Hematology Source Type: research